Publications by authors named "Emad E Khoury"

Article Synopsis
  • - Congestive heart failure (HF) results from impaired heart function leading to reduced blood flow, which triggers neurohormonal systems causing fluid retention and symptoms like dyspnea and fatigue.
  • - The heart and kidneys interact in HF through mechanisms like reduced blood flow and renal perfusion, leading to hypoxia in the renal tubules and further complications due to the activation of systems like RAAS and SNS.
  • - Despite the presence of beneficial hormones like ANP and BNP, the negative effects of neurohormonal activation, such as continued sodium and water retention, dominate, contributing to worsening heart health and renal function.
View Article and Find Full Text PDF

Congestive heart failure (CHF) often leads to progressive cardiac hypertrophy and salt/water retention. However, its pathogenesis remains largely unclarified. Corin, a cardiac serine protease, is responsible for converting proANP and proBNP to biologically active peptides.

View Article and Find Full Text PDF
Article Synopsis
  • * The study demonstrated that angiotensin II treatment significantly reduced NHE8 protein levels in A549 cells, suggesting a regulatory mechanism in response to hypertension.
  • * NHE8 exhibited varying levels in CHF rats, with increased abundance in the early stages of heart failure but decreased levels in more advanced stages, indicating its potential role in lung fluid balance during heart failure.
View Article and Find Full Text PDF

Congestive heart failure (CHF) is often associated with kidney and pulmonary dysfunction. Activation of the renin-angiotensin-aldosterone system (RAAS) contributes to avid sodium retention, cardiac hypertrophy and oedema formation, including lung congestion. While the status of the classic components of RAAS such as renin, angiotensin converting enzyme (ACE), angiotensin II (Ang II) and angiotensin II receptor AT-1 is well studied in CHF, the expression of angiotensin converting enzyme-2 (ACE2), a key enzyme of angiotensin 1-7 (Ang 1-7) generation in the pulmonary, cardiac and renal systems has not been studied thoroughly in this clinical setting.

View Article and Find Full Text PDF

The thiazolidinedione (TZD) class of Peroxisome proliferator-activated receptor gamma agonists has restricted clinical use for diabetes mellitus due to fluid retention and potential cardiovascular risks. These side effects are attributed in part to direct salt-retaining effect of TZDs at the renal collecting duct. A recent study from our group revealed that prolonged rosiglitazone (RGZ) treatment caused no Na+/H O retention or up-regulation of Na transport-linked channels/transporters in experimental congestive heart failure (CHF) induced by surgical aorto-caval fistula (ACF).

View Article and Find Full Text PDF

Background: Congestive heart failure (CHF) entails a complex interaction between the heart and the kidney that represents a clinical entity called cardiorenal syndrome (CRS). One of the mechanisms underlying CRS includes increased intra-abdominal pressure (IAP). We examined the effect of elevated IAP on kidney function in rats with low- and high-output CHF.

View Article and Find Full Text PDF

Congestive heart failure (CHF) often leads to progressive cardiac hypertrophy and salt/water retention as evident by peripheral and lung edema. Although the pathogenesis of CHF remains largely unclarified, it is widely accepted that neurohormonal changes and inflammatory processes are profoundly involved in structural and functional deterioration of vital organs including, heart, kidney and lungs. Corin, a cardiac serine protease, is responsible for converting pro-ANP and pro-BNP to biologically active natriuretic peptides (NPs).

View Article and Find Full Text PDF

The ever-growing global burden of congestive heart failure (CHF) and type 2 diabetes mellitus (T2DM) as well as their co-existence necessitate that anti-diabetic pharmacotherapy will modulate the cardiovascular risk inherent to T2DM while complying with the accompanying restrictions imposed by CHF. The thiazolidinedione (TZD) family of peroxisome proliferator-activated receptor γ (PPARγ) agonists initially provided a promising therapeutic option in T2DM owing to anti-diabetic efficacy combined with pleiotropic beneficial cardiovascular effects. However, the utility of TZDs in T2DM has declined in the past decade, largely due to concomitant adverse effects of fluid retention and edema formation attributed to salt-retaining effects of PPARγ activation on the nephron.

View Article and Find Full Text PDF